These effects were also observed in paclitaxel-resistant SKOV-3 and CAOV-3 ovarian cancer cells, where the anti-IL-6 antibody siltuximab increased paclitaxel sensitivity, leading to lower cell viability and decreased IC50 values [45]. This evidence concerns the gene IL6 and ovarian carcinoma.